Changing Times for CLN2 Disease: The Era of Enzyme Replacement Therapy
Nicola Specchio, Nicola Pietrafusa, Marina Trivisano Rare and Complex Epilepsy Unit, Department of Neuroscience, Bambino Gesù Children’s Hospital, IRCCS, Rome, ItalyCorrespondence: Nicola SpecchioDepartment of Neuroscience, Bambino Ges ...
Specchio N, Pietrafusa N, Trivisano M
doaj +5 more sources
MRI in CLN2 Disease Patients: Subtle Features That Support an Early Diagnosis [PDF]
Neuronal ceroid lipofuscinosis type 2 (CLN2) disease is a rare, paediatric-onset, neurodegenerative disorder characterised in its early stages by language delay, seizures and loss of motor function. It is rapidly progressive and ultimately results in the premature death of patients.
Cengiz Havalı +2 more
exaly +8 more sources
Managing CLN2 Disease: A Treatable Neurodegenerative Condition Among Other Treatable Early Childhood Epilepsies [PDF]
Introduction: Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a rare pediatric neurodegenerative condition, which is usually fatal by mid-adolescence. Seizures are one of the most common early symptoms of CLN2 disease, but patients often experience language deficits, movement disorders, and behavioral problems.
Igor Prpić +2 more
exaly +5 more sources
Clinical management and diagnosis of CLN2 disease: consensus of the Brazilian experts group
Neuronal ceroid lipofuscinosis type 2 (CLN2) is a rare neurodegenerative genetic disease that affects children in early life. Its classic form is rapidly progressive, leading to death within the first 10 years.
Leticia Pereira de Brito Sampaio +8 more
doaj +6 more sources
Study of Intraventricular Cerliponase Alfa for CLN2 Disease [PDF]
Recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (CLN2) disease, a rare lysosomal disorder that causes progressive dementia in children.In a multicenter, open-label study, we evaluated the effect of intraventricular infusion of ...
Jonathan P. Dyke +2 more
exaly +6 more sources
Psychometric Validation of the CLN2 Quality of Life Questionnaire in Participants With CLN2 Disease Treated With Cerliponase Alfa [PDF]
Objectives: This study evaluated the psychometric properties of the ceroid lipofuscinosis type 2 Quality of Life (CLN2 QoL) questionnaire. Methods: Data from children with CLN2 disease aged 3–16 years receiving cerliponase alfa in the BMN 190-201 and BMN 190-202 clinical studies, collected via purposive sampling, were used to assess convergent and ...
Angela Schulz +2 more
exaly +4 more sources
Evidence of the impact of CLN2 and CLN3 Batten disease on families in the United Kingdom [PDF]
Background Neuronal Ceroid Lipofuscinoses (NCLs), also known as Batten disease, are a group of inherited neurodegenerative disorders that mostly arise in childhood.
Sara E. Mole +14 more
doaj +6 more sources
Neurofilament light is a treatment‐responsive biomarker in CLN2 disease [PDF]
Objective Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a rare, progressive, fatal neurodegenerative pediatric disorder resulting from deficiencies of the lysosomal enzyme tripeptidyl peptidase 1 that are caused by mutations in TPP1 ...
Yuanbin Ru +12 more
doaj +3 more sources
Physiotherapy for Children with CLN2 Disease [PDF]
CLN2 disease (neuronal ceroid lipofuscinosis type 2) is a rare, genetic, paediatric-onset, neurodegenerative lysosomal storage disorder characterised by seizures, ataxia, rapid loss of motor function and language ability, dementia, visual loss and early ...
Ina von Löbbecke
doaj +4 more sources
Management Strategies for CLN2 Disease [PDF]
CLN2 disease (neuronal ceroid lipofuscinosis type 2) is a rare, autosomal recessive, pediatric-onset, rapidly progressive neurodegenerative lysosomal storage disorder caused by tripeptidyl peptidase 1 (TPP1) enzyme deficiency, and is characterized by language delay, seizures, rapid cognitive and motor decline, blindness, and early death.
Williams, Ruth E. +25 more
openaire +5 more sources

